These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30590239)

  • 1. Adherence to oral disease-modifying therapy in multiple sclerosis patients: A systematic review.
    Yoon EL; Cheong WL
    Mult Scler Relat Disord; 2019 Feb; 28():104-108. PubMed ID: 30590239
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral agents in multiple sclerosis.
    Lorefice L; Fenu G; Frau J; Coghe GC; Marrosu MG; Cocco E
    Antiinflamm Antiallergy Agents Med Chem; 2015; 14(1):15-25. PubMed ID: 25924620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
    Kretzschmar B; Pellkofer H; Weber MS
    Curr Neurol Neurosci Rep; 2016 Apr; 16(4):38. PubMed ID: 26944956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
    Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
    Pistono C; Osera C; Boiocchi C; Mallucci G; Cuccia M; Bergamaschi R; Pascale A
    Pharmacol Res; 2017 Jun; 120():279-293. PubMed ID: 28396093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study.
    Setayeshgar S; Kingwell E; Zhu F; Zhang T; Carruthers R; Marrie RA; Evans C; Tremlett H
    Mult Scler Relat Disord; 2019 Jan; 27():364-369. PubMed ID: 30476872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis.
    Earla JR; Li J; Hutton GJ; Bentley JP; Aparasu RR
    Mult Scler Relat Disord; 2024 May; 85():105539. PubMed ID: 38574721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis.
    Desai RJ; Mahesri M; Gagne JJ; Hurley E; Tong A; Chitnis T; Minden S; Spettell CM; Matlin OS; Shrank WH; Choudhry NK
    J Manag Care Spec Pharm; 2019 Jan; 25(1):113-121. PubMed ID: 30589630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
    Kalincik T; Kubala Havrdova E; Horakova D; Izquierdo G; Prat A; Girard M; Duquette P; Grammond P; Onofrj M; Lugaresi A; Ozakbas S; Kappos L; Kuhle J; Terzi M; Lechner-Scott J; Boz C; Grand'Maison F; Prevost J; Sola P; Ferraro D; Granella F; Trojano M; Bergamaschi R; Pucci E; Turkoglu R; McCombe PA; Pesch VV; Van Wijmeersch B; Solaro C; Ramo-Tello C; Slee M; Alroughani R; Yamout B; Shaygannejad V; Spitaleri D; Sánchez-Menoyo JL; Ampapa R; Hodgkinson S; Karabudak R; Butler E; Vucic S; Jokubaitis V; Spelman T; Butzkueven H
    J Neurol Neurosurg Psychiatry; 2019 Apr; 90(4):458-468. PubMed ID: 30636699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
    Guarnera C; Bramanti P; Mazzon E
    Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life use of oral disease-modifying treatments in Austria.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
    Acta Neurol Scand; 2019 Jul; 140(1):32-39. PubMed ID: 30958901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.
    Bollo L; Guerra T; Bavaro DF; Monno L; Saracino A; Angarano G; Paolicelli D; Trojano M; Iaffaldano P
    J Neurol Sci; 2020 Sep; 416():117011. PubMed ID: 32650143
    [No Abstract]   [Full Text] [Related]  

  • 14. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
    Nixon R; Bergvall N; Tomic D; Sfikas N; Cutter G; Giovannoni G
    Adv Ther; 2014 Nov; 31(11):1134-54. PubMed ID: 25414048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Agents for Relapsing Forms of Multiple Sclerosis.
    Straus Farber R; Harel A; Lublin F
    Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist.
    Eckstein C; Bhatti MT
    Surv Ophthalmol; 2016; 61(3):318-32. PubMed ID: 26703886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Therapies for Multiple Sclerosis.
    Faissner S; Gold R
    Cold Spring Harb Perspect Med; 2019 Jan; 9(1):. PubMed ID: 29500302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
    English C; Aloi JJ
    Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence to oral disease-modifying therapies in multiple sclerosis patients.
    Lattanzi S; Danni M; Taffi R; Cerqua R; Carlini G; Pulcini A; Provinciali L; Silvestrini M
    J Neurol; 2017 Nov; 264(11):2325-2329. PubMed ID: 28831550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.
    Laplaud DA; Casey R; Barbin L; Debouverie M; De Sèze J; Brassat D; Wiertlewski S; Brochet B; Pelletier J; Vermersch P; Edan G; Lebrun-Frenay C; Clavelou P; Thouvenot E; Camdessanché JP; Tourbah A; Stankoff B; Al Khedr A; Cabre P; Lubetzki C; Papeix C; Berger E; Heinzlef O; Debroucker T; Moreau T; Gout O; Bourre B; Wahab A; Labauge P; Magy L; Defer G; Guennoc AM; Maubeuge N; Labeyrie C; Patry I; Nifle C; Casez O; Michel L; Rollot F; Leray E; Vukusic S; Foucher Y;
    Neurology; 2019 Aug; 93(7):e635-e646. PubMed ID: 31300547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.